In Vitro Evaluation of the Virucidal Activity of Different Povidone-Iodine Formulations Against Murine and Human Coronaviruses.
Anti-infective agents
Coronavirus
Povidone–iodine
SARS-CoV-2
Virus inactivation
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
27
07
2021
accepted:
13
09
2021
pubmed:
29
9
2021
medline:
29
9
2021
entrez:
28
9
2021
Statut:
ppublish
Résumé
Polyvinylpyrrolidone-iodine (PVP-I) demonstrates broad-spectrum anti-infective activity and is available in different formulations for oral rinse and topical use in medical and personal care settings. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has underscored the need to supplement available preventive strategies. We assessed virucidal activity of PVP-I formulations, including 0.5% (w/v) solution, 5.0% (w/v) solution, 7.5% (w/v) scrub, and 10.0% (w/v) solution, versus placebos when challenged with coronaviruses in two in vitro studies. Murine coronavirus strain A59 (American Type Culture Collection [ATCC] All active PVP-I formulations in study 1 demonstrated virucidal activity at 15 s, with mean log Both studies demonstrated in vitro virucidal activity of PVP-I formulations when challenged with SARS-CoV-2 surrogate coronaviruses. Although promising, further investigations are needed to evaluate SARS-CoV-2 inactivation.
Identifiants
pubmed: 34581973
doi: 10.1007/s40121-021-00536-1
pii: 10.1007/s40121-021-00536-1
pmc: PMC8477977
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2777-2790Informations de copyright
© 2021. The Author(s).
Références
Barreto R, Barrois B, Lambert J, Malhotra-Kumar S, Santos-Fernandes V, Monstrey S. Addressing the challenges in antisepsis: focus on povidone iodine. Int J Antimicrob Agents. 2020;56:106064. https://doi.org/10.1016/j.ijantimicag.2020.106064 .
doi: 10.1016/j.ijantimicag.2020.106064
pubmed: 32599228
Eggers M. Infectious disease management and control with povidone iodine. Infect Dis Ther. 2019;8:581–93. https://doi.org/10.1007/s40121-019-00260-x .
doi: 10.1007/s40121-019-00260-x
pubmed: 31414403
pmcid: 6856232
Lachapelle J-M, Castel O, Casado AF, et al. Antiseptics in the era of bacterial resistance: a focus on povidone iodine. Future Med. 2013;10:579–92.
Williamson DA, Carter GP, Howden BP. Current and emerging topical antibacterials and antiseptics: agents, action, and resistance patterns. Clin Microbiol Rev. 2017;30:827–60. https://doi.org/10.1128/CMR.00112-16 .
doi: 10.1128/CMR.00112-16
pubmed: 28592405
pmcid: 5475228
Eggers M, Eickmann M, Kowalski K, Zorn J, Reimer K. Povidone-iodine hand wash and hand rub products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified vaccinia virus Ankara, the new European test virus for enveloped viruses. BMC Infect Dis. 2015;15:375. https://doi.org/10.1186/s12879-015-1111-9 .
doi: 10.1186/s12879-015-1111-9
pubmed: 26381737
pmcid: 4574578
Eggers M, Eickmann M, Zorn J. Rapid and effective virucidal activity of povidone-iodine products against Middle East respiratory syndrome coronavirus (MERS-CoV) and modified Vaccinia virus Ankara (MVA). Infect Dis Ther. 2015;4:491–501. https://doi.org/10.1007/s40121-015-0091-9 .
doi: 10.1007/s40121-015-0091-9
pubmed: 26416214
pmcid: 4675768
Kawana R, Kitamura T, Nakagomi O, et al. Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. Dermatol. 1997;195(Suppl 2):29–35. https://doi.org/10.1159/000246027 .
doi: 10.1159/000246027
Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104:246–51. https://doi.org/10.1016/j.jhin.2020.01.022 .
doi: 10.1016/j.jhin.2020.01.022
pubmed: 32035997
pmcid: 7132493
Food and Drug Administration, Health and Human Services. Safety and effectiveness of health care antiseptics; topical antimicrobial drug products for over-the-counter human use (Docket No. FDA-2015-N-0101; final rule). Fed Reg. 2017;82:60474–503.
Leaper DJ, Durani P. Topical antimicrobial therapy of chronic wounds healing by secondary intention using iodine products. Int Wound J. 2008;5:361–8. https://doi.org/10.1111/j.1742-481X.2007.00406.x .
doi: 10.1111/j.1742-481X.2007.00406.x
pubmed: 18494641
pmcid: 7951213
Johns Hopkins University. Coronavirus Resource Center. 2021. https://coronavirus.jhu.edu/map.html . Accessed 21 Apr 2021.
World Health Organization. SAVE LIVES: Clean Your Hands Campaign. WHO. 2020. https://www.who.int/campaigns/save-lives-clean-your-hands . Accessed 13 Jan 2021.
Ran L, Chen X, Wang Y, Wu W, Zhang L, Tan X. Risk factors of healthcare workers with coronavirus disease 2019: a retrospective cohort study in a designated hospital of Wuhan in China. Clin Infect Dis. 2020;71:2218–21. https://doi.org/10.1093/cid/ciaa287 .
doi: 10.1093/cid/ciaa287
pubmed: 32179890
World Health Organization. COVID 19 landscape of experimental treatments. WHO. 2020. https://www.who.int/publications/i/item/covid-19-landscape-of-experimental-treatments . Accessed 4 Jan 2021.
Anderson DE, Sivalingam V, Kang AEZ, et al. Povidone-iodine demonstrates rapid in vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease. Infect Dis Ther. 2020;9:669–75. https://doi.org/10.1007/s40121-020-00316-3 .
doi: 10.1007/s40121-020-00316-3
pubmed: 32643111
pmcid: 7341475
Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Rapid in-vitro inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using povidone–iodine oral antiseptic rinse. J Prosthodont. 2020;29:529–33. https://doi.org/10.1111/jopr.13209 .
doi: 10.1111/jopr.13209
pubmed: 32511851
Frank S, Brown SM, Capriotti JA, Westover JB, Pelletier JS, Tessema B. In vitro efficacy of a povidone–iodine nasal antiseptic for rapid inactivation of SARS-CoV-2. JAMA Otolaryngol Head Neck Surg. 2020;146:1054–8. https://doi.org/10.1001/jamaoto.2020.3053 .
doi: 10.1001/jamaoto.2020.3053
pubmed: 32940656
Hassandarvish P, Tiong V, Mohamed NA, et al. In vitro virucidal activity of povidone iodine gargle and mouthwash against SARS-CoV-2: implications for dental practice. Br Dent J. 2020;228:900. https://doi.org/10.1038/s41415-020-2402-0 .
doi: 10.1038/s41415-020-2402-0
pubmed: 32591671
pmcid: 7319196
Pelletier JS, Tessema B, Frank S, Westover JB, Brown SM, Capriotti JA. Efficacy of povidone–iodine nasal and oral antiseptic preparations against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Ear Nose Throat J. 2021;100(2_suppl):192S–196S. https://doi.org/10.1177/0145561320957237 .
doi: 10.1177/0145561320957237
pubmed: 32951446
Siddharta A, Pfaender S, Vielle NJ, et al. Virucidal activity of World Health Organization-recommended formulations against enveloped viruses, including Zika, Ebola, and emerging coronaviruses. J Infect Dis. 2017;215:902–6. https://doi.org/10.1093/infdis/jix046 .
doi: 10.1093/infdis/jix046
pubmed: 28453839
Khan MM, Parab SR, Paranjape M. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic. Am J Otolaryngol. 2020;41:102618. https://doi.org/10.1016/j.amjoto.2020.102618 .
doi: 10.1016/j.amjoto.2020.102618
pubmed: 32574894
pmcid: 7301800
Mohamed NA, Baharom N, Wan Sulaiman WS, et al. Early viral clearance among COVID-19 patients when gargling with povidone–iodine and essential oils: a clinical trial. Int Med J. 2020;27:651–4. https://doi.org/10.1101/2020.09.07.20180448 .
doi: 10.1101/2020.09.07.20180448
Yan CH, Bleier BS. Prophylactic and therapeutic topical povidone-iodine in coronavirus disease 2019 (COVID-19): what is the evidence? Int Forum Allergy Rhinol. 2020;10:1271–3. https://doi.org/10.1002/alr.22735 .
doi: 10.1002/alr.22735
pubmed: 33118690
Mady LJ, Kubik MW, Baddour K, Snyderman CH, Rowan NR. Consideration of povidone-iodine as a public health intervention for COVID-19: utilization as “Personal Protective Equipment” for frontline providers exposed in high-risk head and neck and skull base oncology care. Oral Oncol. 2020;105: 104724. https://doi.org/10.1016/j.oraloncology.2020.104724 .
doi: 10.1016/j.oraloncology.2020.104724
pubmed: 32317139
pmcid: 7161480
Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018;100:163–88. https://doi.org/10.1016/bs.aivir.2018.01.001 .
doi: 10.1016/bs.aivir.2018.01.001
pubmed: 29551135
pmcid: 7112090
Cui W, Cui S, Chen C, et al. The crystal structure of main protease from mouse hepatitis virus A59 in complex with an inhibitor. Biochem Biophys Res Commun. 2019;511:794–9. https://doi.org/10.1016/j.bbrc.2019.02.105 .
doi: 10.1016/j.bbrc.2019.02.105
pubmed: 30833083
pmcid: 7185540
Lissenberg A, Vrolijk MM, van Vliet ALW, et al. Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory hemagglutinin esterase protein display reduced fitness in vitro. J Virol. 2005;79:15054–63. https://doi.org/10.1128/JVI.79.24.15054-15063.2005 .
doi: 10.1128/JVI.79.24.15054-15063.2005
pubmed: 16306576
pmcid: 1316008
Yang Z, Du J, Chen G, et al. Coronavirus MHV-A59 infects the lung and causes severe pneumonia in C57BL/6 mice. Virol Sin. 2014;29:393–402. https://doi.org/10.1007/s12250-014-3530-y .
doi: 10.1007/s12250-014-3530-y
pubmed: 25547683
pmcid: 7090691
Chakraborty A, Diwan A. NL63: a better surrogate virus for studying SARS-CoV-2. Integr Mol Med. 2020;7:1–9. https://doi.org/10.15761/IMM.1000408 .
doi: 10.15761/IMM.1000408
Ramakrishnan MA. Determination of 50% endpoint titer using a simple formula. World J Virol. 2016;5:85–6. https://doi.org/10.5501/wjv.v5.i2.85 .
doi: 10.5501/wjv.v5.i2.85
pubmed: 27175354
pmcid: 4861875
Guidance on SARS-CoV-2 surrogate selection (ASTM standard under consideration). ASTM. 2020. https://www.astm.org/COMMIT/GuidanceCOVID19SurrogateSel_April242020press.pdf . Accessed 10 Sep 2021.
Eggers M, Koburger-Janssen T, Ward LS, Newby C, Müller S. Bactericidal and virucidal activity of povidone–iodine and chlorhexidine gluconate cleansers in an in vivo hand hygiene clinical simulation study. Infect Dis Ther. 2018;7:235–47. https://doi.org/10.1007/s40121-018-0202-5 .
doi: 10.1007/s40121-018-0202-5
pubmed: 29761329
pmcid: 5986686
European Committee for Standardization. EN 14476:2013+A2:2019 Chemical disinfectants and antiseptics—quantitative suspension test for the evaluation of virucidal activity in the medical area—test method and requirements (Phase 2/Step 1). 2019. https://standards.iteh.ai/catalog/standards/cen/10065fd9-2d40-4f02-bccd-48206b72f108/en-14476-2013a2-2019 . Accessed 10 Sept 2021.
Hooton TM, Fennell CL, Clark AM, Stamm WE. Nonoxynol-9: differential antibacterial activity and enhancement of bacterial adherence to vaginal epithelial cells. J Infect Dis. 1991;164:1216–9. https://doi.org/10.1093/infdis/164.6.1216 .
doi: 10.1093/infdis/164.6.1216
pubmed: 1659602
Klebanoff SJ. Effects of the spermicidal agent nonoxynol-9 on vaginal microbial flora. J Infect Dis. 1992;165:19–25. https://doi.org/10.1093/infdis/165.1.19 .
doi: 10.1093/infdis/165.1.19
pubmed: 1309374
US Food and Drug Administration. FDA letter regarding deferral of povidone–iodine. 2017. https://www.regulations.gov/document?D=FDA-2015-N-0101-1326 . Accessed 7 Jan 2021.
Suchomel M, Kundi M, Pittet D, Rotter ML. Modified World Health Organization hand rub formulations comply with European efficacy requirements for preoperative surgical hand preparations. Infect Control Hosp Epidemiol. 2013;34:245–50. https://doi.org/10.1086/669528 .
doi: 10.1086/669528
pubmed: 23388358
Suchomel M, Steinmann J, Kampf G. Efficacies of the original and modified World Health Organization-recommended hand-rub formulations. J Hosp Infect. 2020;106:264–70. https://doi.org/10.1016/j.jhin.2020.08.006 .
doi: 10.1016/j.jhin.2020.08.006
pubmed: 32800826
pmcid: 7423627
Koburger T, Hübner N-O, Braun M, Siebert J, Kramer A. Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. J Antimicrob Chemother. 2010;65:1712–9. https://doi.org/10.1093/jac/dkq212 .
doi: 10.1093/jac/dkq212
pubmed: 20551215
Davies K, Buczkowski H, Welch SR, et al. Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes. J Gen Virol. 2021;102: https://doi.org/10.1099/jgv.0.001578 .
doi: 10.1099/jgv.0.001578
pmcid: 8290272
Xu C, Wang A, Hoskin ER, et al. Differential effects of antiseptic mouth rinses on SARS-CoV-2 infectivity in vitro. Pathogens. 2021;10:272. https://doi.org/10.3390/pathogens10030272 .
doi: 10.3390/pathogens10030272
pubmed: 33804294
pmcid: 8001756
Hassandarvish P, Tiong V, Mohamed NA, et al. In vitro virucidal activity of povidone iodine gargle and mouthwash against SARS-CoV-2: implications for dental practice. Br Dent J. 2020. https://doi.org/10.1038/s41415-020-2402-0 .
doi: 10.1038/s41415-020-2402-0
pubmed: 33303923
pmcid: 7726738
Anderson DE, Sivalingam V, Kang AEZ, et al. Povidone-iodine demonstrates rapid in vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease. Infect Dis Ther. 2020;9:669–75. https://doi.org/10.1007/s40121-020-00316-3 .
doi: 10.1007/s40121-020-00316-3
pubmed: 32643111
pmcid: 7341475
Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Rapid in-vitro inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using povidone-iodine oral antiseptic rinse. J Prosthodont. 2020;29:529–33. https://doi.org/10.1111/jopr.13209 .
doi: 10.1111/jopr.13209
pubmed: 32511851
Tadakamadla J, Boccalari E, Rathore V, Dolci C, Tartaglia GM, Tadakamadla SK. In vitro studies evaluating the efficacy of mouth rinses on Sars-Cov-2: a systematic review. J Infect Public Health. 2021;14:1179–85. https://doi.org/10.1016/j.jiph.2021.07.020 .
doi: 10.1016/j.jiph.2021.07.020
pubmed: 34399189
pmcid: 8339500
Guenezan J, Garcia M, Strasters D, et al. Povidone iodine mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-19: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2021;147:400–1. https://doi.org/10.1001/jamaoto.2020.5490 .
doi: 10.1001/jamaoto.2020.5490
pubmed: 33538761
Seneviratne CJ, Balan P, Ko KKK, et al. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore. Infection. 2021;49:305–11. https://doi.org/10.1007/s15010-020-01563-9 .
doi: 10.1007/s15010-020-01563-9
pubmed: 33315181